Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One. 2012;7(4):e33656. doi: 10.1371/journal.pone.0033656. Epub 2012 Apr 2.
The objectives of this study were to evaluate the effects of tanshinones from a Chinese herb Salvia Miltiorrhiza on the growth of breast cancer cells, and to elucidate cellular and molecular mechanisms of action. Tanshinones showed the dose-dependent effect on the growth inhibition of breast cancer cells in vitro, with tanshinone I (T1) the most potent agent. T1 was also the only tanshinone to have potent activity in inhibiting the growth of the triple-negative breast cancer cell line MDA-MB231. T1 caused cell cycle arrests of both estrogen-dependent and estrogen-independent cell lines associated with alterations of cyclinD, CDK4 and cyclinB, and induced breast cancer cell apoptosis associated with upregulation of c-PARP and downregulation of survivin and Aurora A. Among these associated biomarkers, Aurora A showed the most consistent pattern with the anti-growth activity of tanshinones. Overexpression of Aurora A was also verified in breast tumors. The gene function assay showed that knockdown of Aurora A by siRNA dramatically reduced the growth-inhibition and apoptosis-induction activities of T1, suggesting Aurora A as an important functional target of T1 action. On the other hand, tanshinones had much less adverse effects on normal mammary epithelial cells. Epigenetic mechanism studies showed that overexpression of Aurora A gene in breast cancer cells was not regulated by gene promoter DNA methylation, but by histone acetylation. T1 treatment significantly reduced acetylation levels of histone H3 associated with Aurora A gene. Our results supported the potent activity of T1 in inhibiting the growth of breast cancer cells in vitro in part by downregulation of Aurora A gene function. Our previous studies also demonstrated that T1 had potent anti-angiogenesis activity and minimal side effects in vivo. Altogether, this study warrants further investigation to develop T1 as an effective and safe agent for the therapy and prevention of breast cancer.
本研究旨在评估丹参酮类化合物(一种来自中药丹参的物质)对乳腺癌细胞生长的影响,并阐明其细胞和分子作用机制。丹参酮类化合物在体外对乳腺癌细胞的生长抑制具有剂量依赖性,其中丹参酮 I(T1)作用最强。T1 也是唯一对三阴性乳腺癌细胞系 MDA-MB231 具有抑制生长活性的丹参酮。T1 引起依赖和不依赖雌激素的细胞系细胞周期停滞,与细胞周期蛋白 D、CDK4 和细胞周期蛋白 B 的改变有关,并诱导乳腺癌细胞凋亡,与 c-PARP 的上调和 survivin 和 Aurora A 的下调有关。在这些相关生物标志物中,Aurora A 与丹参酮类化合物的抗生长活性最为一致。在乳腺癌肿瘤中也证实了 Aurora A 的过表达。基因功能分析表明,siRNA 下调 Aurora A 显著降低了 T1 的生长抑制和凋亡诱导活性,表明 Aurora A 是 T1 作用的重要功能靶点。另一方面,丹参酮类化合物对正常乳腺上皮细胞的不良反应要小得多。表观遗传机制研究表明,乳腺癌细胞中 Aurora A 基因的过表达不受基因启动子 DNA 甲基化的调控,而是受组蛋白乙酰化的调控。T1 处理显著降低了与 Aurora A 基因相关的组蛋白 H3 的乙酰化水平。我们的研究结果支持 T1 通过下调 Aurora A 基因功能在体外抑制乳腺癌细胞生长的活性。我们之前的研究还表明,T1 具有很强的抗血管生成活性和体内最小的副作用。总之,这项研究有必要进一步研究开发 T1 作为治疗和预防乳腺癌的有效和安全药物。